



**Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #45-24) 07/16/2024 Invivo
Therapeutics Corporation. (NVIVQ)**

Notice has been received that the above Company's Joint Plan of Liquidation of Invivo Therapeutics Corporation and Invivo Therapeutics Holdings Corp. became effective on 07/12/2024. Pursuant to the plan, Only if all Class 5 claims are satisfied in full, and except to the extent that a holder of an Interest aim agrees to less favorable treatment, each holder of such Allowed Interest shall receive its pro rata share of the Beneficial Trust Interests, which Beneficial Trust Interests shall entitle the holders thereof to receive their pro rata share of the Liquidation Trust Assets. See the Company's Joint Plan of Liquidation for additional information.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations - 1-866-776-0800.

¹ See *e.g., In re: Invivo Therapeutics, Corporation, et al., Debtors*. Chapter 11 Case No. 24-10137 (MFW) (Jointly Administered) Joint Plan of Liquidation of Invivo Therapeutics Corporation and Invivo Therapeutics Holdings Corp.